본문 바로가기
bar_progress

Text Size

Close

Dongyang Life Launches Special Contract Guaranteeing Targeted Anticancer Drug Treatment

Dongyang Life Launches Special Contract Guaranteeing Targeted Anticancer Drug Treatment Dongyang Life Insurance launched the 'Targeted Anticancer Drug Approval Treatment Special Contract (Renewable)' guaranteeing targeted anticancer drug treatment on the 22nd.


[Asia Economy Reporter Oh Hyung-gil] Dongyang Life Insurance launched the 'Targeted Anticancer Drug Authorized Treatment Rider (Renewable)' on the 22nd, which guarantees targeted anticancer drug treatment.


Targeted anticancer drug treatment is a therapeutic technique that uses targeted anticancer agents to block the activity of specific molecules involved in the growth and progression of cancer, preventing the cancer from growing and spreading while minimizing the side effects of anticancer drug treatment.


The Targeted Anticancer Drug Authorized Treatment Rider is designed to be subscribed at a premium about 16% lower than cancer diagnosis products.


If diagnosed with cancer, colorectal mucosal cancer, other skin cancers, or thyroid cancer, and targeted anticancer drug authorized treatment is performed for direct treatment, the insurance pays up to 50 million KRW for the first treatment only.


However, if the diagnosis is confirmed within one year after insurance subscription, only 50% of the coverage amount is paid, and coverage is not provided for carcinoma in situ or borderline tumors.


Subscription is available from ages 15 to 70, and coverage can be extended up to age 100 through renewal. This product can be subscribed as the main contract with Suho Cheonsa Naega Mandeuneun Bojang Insurance or Suho Cheonsa Silsok Hanaro Cancer Insurance through the direct channel.


A Dongyang Life Insurance official stated, "Targeted anticancer drug treatment has fewer side effects compared to conventional chemotherapy, but it is often classified as non-reimbursable under health insurance, resulting in a high cost burden," adding, "We developed a product that focuses on coverage for targeted anticancer drug prescriptions at an affordable premium so that patients can concentrate on treatment with peace of mind."


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top